What is Immunome's cash ratio?

Immunome (IMNM) reported cash ratio of 21.3× in Q1 2026.

How has Immunome's cash ratio changed year-over-year?

Immunome's cash ratio increased by 154.1% year-over-year, from 8.4× to 21.3×.

What is the long-term trend for Immunome's cash ratio?

Over 5 years (2020 to 2025), Immunome's cash ratio has grown at a 2.1% compound annual growth rate (CAGR), from 13.1× to 14.5×.

What does cash ratio mean?

Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.

Immunome IMNM Cash ratio

Cash ratio at other companies

PfizerPFE

0.1×0.0×

Arcus BiosciencesRCUS

1×0.0×

Nuvation BioNUVB

1.6×+0.7×

SELLAS Life Sciences Group, Inc.SLS

16.6×+12.5×

ArriVent BioPharma, Inc.AVBP

2.5×-1.4×

IDEAYA Biosciences, Inc.IDYA

2.4×-0.1×

Other financials

Income statement

See full

Revenue--100%

Operating income-$59.3M-32.9%

Net income-$53.8M-29.3%

EPS (diluted)-$0.48+7.7%

Balance sheet

See full

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total equity$588.7M+91.7%

Total assets$619.8M+80.9%

Cash flow

See full

Operating cash flow-$58.6M-10.5%

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation

See full

Market cap$2.19B+323%

Enterprise value$1.61B+470%

P/S545.2×+498×

Profitability

See full

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

See full

Return on equity-50.1%-10.8pp

Debt / equity0×0.0×

Current ratio21.7×+11.2×

Where this comes from

Calculated from Immunome’s reported figures.

cash and equivalents/total current liabilities=21.3×

Based on the most recent quarter.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immunome's cash ratio?: Immunome (IMNM) reported cash ratio of 21.3× in Q1 2026.
How has Immunome's cash ratio changed year-over-year?: Immunome's cash ratio increased by 154.1% year-over-year, from 8.4× to 21.3×.
What is the long-term trend for Immunome's cash ratio?: Over 5 years (2020 to 2025), Immunome's cash ratio has grown at a 2.1% compound annual growth rate (CAGR), from 13.1× to 14.5×.
What does cash ratio mean?: Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.